E-viri
Recenzirano
Odprti dostop
-
Lyke, Kirsten E; Atmar, Robert L; Dominguez Islas, Clara; Posavad, Christine M; Deming, Meagan E; Branche, Angela R; Johnston, Christine; El Sahly, Hana M; Edupuganti, Srilatha; Mulligan, Mark J; Jackson, Lisa A; Rupp, Richard E; Rostad, Christina A; Coler, Rhea N; Bäcker, Martín; Kottkamp, Angelica C; Babu, Tara M; Dobrzynski, David; Martin, Judith M; Brady, Rebecca C; Frenck, Jr, Robert W; Rajakumar, Kumaravel; Kotloff, Karen; Rouphael, Nadine; Szydlo, Daniel; PaulChoudhury, Rahul; Archer, Janet I; Crandon, Sonja; Ingersoll, Brian; Eaton, Amanda; Brown, Elizabeth R; McElrath, M Juliana; Neuzil, Kathleen M; Stephens, David S; Post, Diane J; Lin, Bob C; Serebryannyy, Leonid; Beigel, John H; Montefiori, David C; Roberts, Paul C
npj vaccines, 07/2023, Letnik: 8, Številka: 1Journal Article
As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a single booster dose of NVX-CoV2373 in adults primed with either Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines. NVX-CoV2373 as a heterologous booster was immunogenic and associated with no safety concerns through Day 91. Fold-rises in PsVNA titers from baseline (Day 1) to Day 29 were highest for prototypic D614G variant and lowest for more recent Omicron sub-lineages BQ.1.1 and XBB.1. Peak humoral responses against all SARS-CoV-2 variants were lower in those primed with Ad26.COV2.S than with mRNA vaccines. Prior SARS CoV-2 infection was associated with substantially higher baseline PsVNA titers, which remained elevated relative to previously uninfected participants through Day 91. These data support the use of heterologous protein-based booster vaccines as an acceptable alternative to mRNA or adenoviral-based COVID-19 booster vaccines. This trial was conducted under ClinicalTrials.gov: NCT04889209.
